Company: GANX
Filing Date: 2025-07-15
Form Type: 424B5
Source: 0001104659-25-068103
Chunk: 29

Company: Gain Therapeutics, Inc.
Filing Date: 2025-07-15
Form: 424B5
Chunk 29
---
arrants sold in this offering, in any combination thereof, firmly committed in this offering at a price of $ per share or $ per Common Warrant to purchase one share of common stock, in each case, less the underwriting discounts and commissions. The underwriter may exercise the option solely to cover over-allotments, if any, made in connection with this offering. If any additional shares of our common stock and/or Common Warrants are purchased pursuant to the over-allotment option, the underwriter will offer these additional shares of our common stock and/or Common Warrants on the same terms as those on which the other shares of common stock and Common Warrants are being offered hereby.

#### Underwriter’s Warrants
Upon the closing of this offering, we have agreed to issue to Newbridge, or its designees, warrants (the “Underwriter Warrants”) to purchase a number of shares of common stock equal to an aggregate of 7% of the total number of shares sold in this offering (including the shares of common stock underlying the Pre-Funded Warrants). The Underwriter Warrants will be exercisable at a per share exercise price equal to 125% of the public offering price per share of common stock sold in this offering. The Underwriter Warrants are exercisable at any time and from time to time, in whole or in part, during the four-and-one-half year period commencing six months after the closing date of this offering.

The Underwriter Warrants and the shares of common stock underlying the Underwriter Warrants have been deemed compensation by the Financial Industry Regulatory Authority, or FINRA, and are therefore subject to a 180-day lock-up pursuant to Rule 5110(e)(1) of FINRA. Neither Newbridge or its permitted assignees under such rule, may sell, transfer, assign, pledge, or hypothecate the Underwriter Warrants or the securities underlying the Underwriter Warrants, nor will Newbridge engage in any hedging, short sale, derivative, put, or call transaction that would result in the effective economic disposition of the Underwriter Warrants or the underlying shares for a period of 180 days from the effective date of the registration statement.

Additionally, the Underwriter Warrants may not be sold, transferred, assigned, pledged or hypothecated for a 180-day period following the effective date of the registration statement except to any underwriter and selected dealer participating in this offering and their bona fide officers or partners. The Underwriter Warrants will provide for adjustment in